Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) has been given a consensus recommendation of “Buy” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $16.00.

ETTX has been the topic of several research analyst reports. SunTrust Banks initiated coverage on shares of Entasis Therapeutics in a research report on Wednesday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research upgraded shares of Entasis Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Friday, January 4th. ValuEngine lowered shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Credit Suisse Group began coverage on shares of Entasis Therapeutics in a research report on Monday, October 22nd. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Wedbush began coverage on shares of Entasis Therapeutics in a research report on Monday, October 22nd. They set an “outperform” rating and a $19.00 price target on the stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Laurion Capital Management LP acquired a new position in Entasis Therapeutics during the third quarter worth about $544,000. Credit Suisse AG acquired a new position in Entasis Therapeutics during the third quarter worth about $757,000. Hound Partners LLC acquired a new position in Entasis Therapeutics during the third quarter worth about $1,117,000. Luminus Management LLC acquired a new position in Entasis Therapeutics during the third quarter worth about $2,130,000. Finally, Sofinnova Ventures Inc acquired a new position in Entasis Therapeutics during the third quarter worth about $12,840,000. Hedge funds and other institutional investors own 66.61% of the company’s stock.

Shares of NASDAQ ETTX traded down $0.44 during trading on Friday, hitting $5.01. The company had a trading volume of 7,700 shares, compared to its average volume of 17,775. Entasis Therapeutics has a fifty-two week low of $3.97 and a fifty-two week high of $13.70.

Entasis Therapeutics (NASDAQ:ETTX) last announced its earnings results on Wednesday, November 14th. The company reported ($20.00) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($19.18). Research analysts predict that Entasis Therapeutics will post -4.68 earnings per share for the current fiscal year.

About Entasis Therapeutics

Entasis Therapeutics Holdings Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing ETX2514SUL, a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, an oral antibiotic monotherapy that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and various antibiotics for gram-negative infections.

See Also: Stock Selection – What is cash flow?

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.